Weight Loss Injections, Mounjaro, and IVF: What Clinics Actually Care About
Questions about Mounjaro and IVF usually come from very real concerns. Clinic BMI thresholds. PCOS or insulin resistance. Being advised to lose weight before treatment while feeling the clock tick. GLP-1 weight loss injections can support metabolic health for some people, while at the same time complicating fertility timelines and decision-making. Here, we’ll explore what we know, what remains unclear, and how to plan safely and confidently around IVF when weight loss injections are part of your picture.
Author
Tassia O’Callaghan
Reviewed by
Kayleigh Hartigan
20 min read
Spotlight:
- Weight loss injections used before IVF are usually GLP-1 receptor agonists, which affect appetite, blood sugar control, and metabolic signalling.
- These medications can support metabolic health and IVF eligibility for some people, particularly where insulin resistance or PCOS is part of the picture.
- They don’t directly improve egg quality, embryos, or IVF success rates, but they can influence how and when treatment happens.
- Timing matters most around embryo transfer, as GLP-1 medications aren’t recommended once pregnancy is possible.
- Different medications stay in the body for different lengths of time, so stopping guidance varies by drug and clinic.
- Decisions work best when weight loss, stabilisation, and IVF are planned together, with personalised advice from your care team.
What are weight loss injections, and how do they work?
Weight loss injections used before IVF usually belong to a group of medications called GLP-1 receptor agonists. These drugs mimic the action of a natural hormone involved in appetite regulation and blood sugar control. [1]
In the body, GLP-1 receptor agonists reduce appetite and increase feelings of fullness, improve insulin sensitivity, lower blood glucose levels, and influence inflammation and metabolic signalling. [2,3,4]
For people with insulin resistance or PCOS, these effects can support more regular ovulation and cycle predictability over time. That is why weight loss injections are sometimes prescribed ahead of IVF, even though they were not designed as fertility medications. [5]
What matters for fertility is context. These medications affect energy intake, hormone signalling, and nutrient absorption. Those factors intersect with egg development, embryo transfer timing, and early pregnancy safety, but they don’t directly improve those elements.
Different types of weight loss medication may have different side effects and different effects on your fertility or IVF protocol and success:
| Medication (brand) | Active ingredient | Typical use | Pregnancy/TTC guidance (general) |
|---|---|---|---|
| Mounjaro | Tirzepatide | Weight loss, type 2 diabetes | Avoid in pregnancy. Recommended to stop at least 1 month before planned pregnancy. [6] |
| Zepbound (US brand) | Tirzepatide | Weight loss | Same pregnancy avoidance principles as tirzepatide products. |
| Ozempic | Semaglutide | Type 2 diabetes (often used off-label for weight loss) | Avoid in pregnancy. Recommended to stop at least 2 months before planned pregnancy. [7] |
| Wegovy | Semaglutide | Weight loss | Avoid in pregnancy. Recommended to stop at least 2 months before planned pregnancy. [8] |
| Rybelsus (oral) | Semaglutide | Type 2 diabetes | Avoid in pregnancy. Recommended to stop at least 2 months before planned pregnancy. [9] |
| Saxenda | Liraglutide | Weight loss | Avoid in pregnancy. Recommended to stop if pregnancy occurs or is planned. [10] |
| Victoza | Liraglutide | Type 2 diabetes | Avoid in pregnancy. Recommended to stop if pregnancy occurs or is planned. [11] |
| Trulicity | Dulaglutide | Type 2 diabetes (some weight loss effect) | Avoid in pregnancy and coordinate timing with clinician. (Clinic-specific washout varies.) [12] |
| Byetta or Bydureon | Exenatide | Type 2 diabetes (some weight loss effect) | Avoid in pregnancy. Some guidance references longer discontinuation windows for certain GLP-1s (exenatide often flagged for a longer buffer). [13] |
| Xenical or Alli | Orlistat | Weight loss | Not routinely recommended in pregnancy due to limited data and nutrition concerns. [14] |
| Mysimba (EU/UK) | Naltrexone + bupropion | Weight loss | Avoid in pregnancy. Recommended to stop at least 2 months before planned pregnancy. [15] |
| Metformin | Metformin | Insulin resistance, PCOS support, type 2 diabetes, not considered a “weight loss” medication | Pregnancy use depends on indication and clinician guidance. |
Do weight loss injections affect IVF?
This is the question most people ask, and the answer depends on where you are in the IVF process and how close pregnancy could be. Weight loss injections interact with IVF differently during preparation, stimulation, and embryo transfer, so timing matters far more than the medication name itself. Clinics are less concerned about use months before treatment and far more focused on exposure once pregnancy becomes possible. Understanding those distinctions helps you plan safely, avoid last-minute delays, and make decisions that support both your health and your fertility timeline.
Egg quality and ovarian response
There is limited direct human data on GLP-1 medications and egg quality. What we do understand comes from metabolic research and fertility physiology.
Improved insulin sensitivity and reduced systemic inflammation can support ovarian function for some people, particularly those with PCOS. That can translate into a more predictable response to stimulation. [5]
At the same time, very rapid weight loss or significant calorie suppression close to egg collection may raise concerns. Eggs take several months to mature, and adequate nutrition supports that process. Clinics often pay attention to hydration, protein intake, and micronutrients during stimulation for this reason. [16]
Embryo development and implantation
There is no direct evidence that GLP-1 drugs harm embryos. The concern here is pregnancy exposure, not embryo quality. But, at the same time, there’s not enough evidence to say that GLP-1s don’t harm embryos, either.
Because these medications are not considered safe in pregnancy, clinics focus heavily on stopping them before embryo transfer. Implantation and early placental development depend on stable hormonal and metabolic conditions.
IVF outcomes overall
Weight loss may improve access to IVF when BMI thresholds apply, reduce anaesthetic and pregnancy-related risks, and support underlying metabolic conditions that complicate treatment. For some people, these changes make IVF safer and more straightforward to proceed with. What weight loss injections do not do is directly increase IVF success rates. Their role is to support overall health and treatment readiness, rather than enhance outcomes in their own right. The key takeaway is simple: timing matters more than the drug itself. [17]
BMI for IVF: What You Need to Know
BMI for IVF is often used by clinics as part of their eligibility criteria, and it can feel like yet another hurdle when you’re ready to start treatment.
Mounjaro and IVF: What clinics are most concerned about
Clinics tend to speak carefully about Mounjaro because the unknowns still matter, particularly in the context of IVF where timing and early pregnancy conditions are closely managed.
Their main concerns include:
- Pregnancy exposure risk, especially in early development: GLP-1 medications are not considered safe in pregnancy, due to lack of evidence and studies, and early embryonic development is a delicate period of rapid cellular change. Clinics prioritise avoiding any exposure during this window, even in the absence of proven harm, because safety data in early pregnancy is limited.
- Long half-life and residual drug levels: Mounjaro stays active in the body for weeks after the final dose. That means stopping the injection does not immediately remove its biological effects, which is why clinics build in buffer periods before embryo transfer rather than relying on last-minute discontinuation. [18]
- Cycle regularity: Hormonal signalling and ovulation patterns can shift while on appetite-suppressing medication and again after stopping. Giving your cycle time to regulate makes it easier to track ovulation, plan treatment timing, and interpret hormone monitoring accurately.
- Nausea, dehydration, and reduced intake during stimulation: Mounjaro and other GLP-1s may cause side effects like nausea and dehydration. Persistent nausea and inadequate nutrition can make it harder to stay well hydrated, tolerate medication, and attend monitoring appointments comfortably. [19]
- Weight to plateau rather than continue dropping: Rapid weight loss is not the goal immediately before pregnancy. Clinics generally prefer to see weight stabilise, as this suggests metabolic balance and reduces the risk of nutritional deficits during the early stages of conception and implantation.
- Areas where evidence is still evolving: There’s limited direct human data on GLP-1 medications and IVF outcomes, particularly around egg quality and implantation. Clinics acknowledge this uncertainty rather than making definitive claims, which informs their cautious approach.
When to stop Mounjaro before embryo transfer
Most fertility clinics recommend stopping Mounjaro well before embryo transfer, at least 1-2 month in advance. The reason is drug clearance and hormonal stabilisation.
Embryo transfer carries a real possibility of pregnancy. Clinics therefore apply stricter rules here than they do for egg collection alone.
Fresh transfers usually involve stopping earlier, because ovarian stimulation and transfer happen in the same cycle. Frozen embryo transfers allow more flexibility, as timing can be planned around medication washout.
But always confirm exact timelines with your clinic and prescribing clinician, as guidance can vary depending on your circumstances and IVF protocol.
How long should you be off Mounjaro before trying to get pregnant?
Most medical guidance advises stopping GLP-1 medications at least 1-2 months before actively trying to conceive. This pause allows the body time to settle into a more stable baseline before pregnancy is possible, which is particularly relevant when planning IVF or timed conception.
How long does Mounjaro stay in your system?
Mounjaro has a long half-life, around 5 days, so it leaves the body gradually rather than overnight, taking around 25 days after your last dose to leave your system. But being “out of your system” doesn’t necessarily mean your body has fully adjusted. Appetite, digestion, and insulin signalling continue to rebalance after stopping.
Clinics build in buffer time for this reason. That buffer supports early pregnancy conditions, not just medication clearance.
What happens if I get pregnant on Mounjaro?
If pregnancy happens while using Mounjaro, the usual advice is to stop the medication as soon as the pregnancy is confirmed. From there, the most important next step is to let both your prescribing clinician and your fertility or maternity care team know promptly, so they can guide you on what happens next.
The recommendation to stop Mounjaro immediately exists because these medications aren’t approved for use in pregnancy, rather than because of known adverse outcomes.
Ozempic, Wegovy, Saxenda, and IVF: Are they treated differently?
Clinically, these medications raise similar fertility considerations, but there are important differences in how they behave in the body that influence clinic guidance and stopping timelines.
- Ozempic and Wegovy (semaglutide): These medications share the same active ingredient and are often treated interchangeably in fertility settings, regardless of brand name. Semaglutide has a long half-life, which means it remains active for weeks after stopping. Because of this, clinics usually recommend a clear washout period before embryo transfer or trying to conceive, focusing on reducing any risk of early pregnancy exposure rather than concerns about ovarian response. [20]
- Saxenda (liraglutide): Saxenda uses an earlier GLP-1 medication with a shorter duration of action and a daily dosing schedule. While this can allow for a quicker physiological adjustment after stopping, clinics still take a cautious approach around pregnancy. The shorter half-life doesn’t remove the need to discontinue before transfer or conception, but it may influence how long a clinic asks you to be off the medication beforehand. [21]
- Mounjaro (tirzepatide): Mounjaro acts on two metabolic receptors and has a longer half-life than many other weight loss injections. This extended activity is why clinics tend to be more specific about stopping timelines, particularly before embryo transfer. The focus remains on ensuring the medication’s effects have fully settled before pregnancy is possible, rather than on differences in IVF stimulation itself. [22]
Using weight loss injections before IVF: When it can make sense
There may be situations where using GLP-1 medications before IVF can support better outcomes, particularly when they’re used as part of a carefully considered plan that takes your wider health and fertility timeline into account, such as:
- Meeting BMI criteria to access treatment: For some people, weight loss injections provide a way to meet clinic or NHS eligibility thresholds, helping remove a barrier to IVF that might otherwise delay or prevent treatment. [23]
- Managing insulin resistance or PCOS: By improving insulin sensitivity and metabolic regulation, GLP-1 medications can help stabilise cycles and hormone signalling for some people, which may create a clearer starting point for IVF planning. [24]
- Reducing surgical and anaesthetic risks: Weight loss can lower the risk of complications during egg collection and reduce physical strain during stimulation, which is why clinics often view metabolic health as part of overall treatment safety. [25]
- Improving metabolic markers before pregnancy: Improvements in blood glucose control, inflammation, and cardiovascular markers can support a healthier transition into pregnancy, particularly where metabolic conditions are part of the picture. [26]
- Supporting mental wellbeing around food and control: For some people, appetite regulation reduces food noise and restores a sense of control over their health, which can feel grounding during an emotionally demanding fertility path.
At the same time, it’s important to acknowledge the trade-offs. Rapid weight loss can put pressure on nutritional intake at a time when consistency matters. Stopping medication can feel physically and emotionally destabilising, especially after a period of appetite suppression. Timelines may also feel stretched when age, ovarian reserve, or previous delays are already weighing heavily.
Because of this, there’s no one-size-fits-all recommendation here. We can’t offer medical advice, and these decisions always depend on individual health history, fertility diagnosis, IVF protocol, and guidance from your prescribing clinician and fertility clinic. What this information can do is help you understand the factors clinics are weighing up, so you’re better prepared for informed, personalised conversations with your care team. These decisions work best when they’re planned collaboratively, rather than rushed under pressure.
Using weight loss injections during IVF: Where clinics draw the line
Most fertility clinics draw a clear distinction between the stimulation phase of IVF and the embryo transfer stage, because the risks they are managing at each point are very different. During ovarian stimulation, the primary focus is how the body responds to fertility medication and how well egg collection can be carried out safely. At this stage, pregnancy is not possible, which is why some (not all) clinics may be comfortable with continued GLP-1 use up to egg retrieval, particularly when the medication is supporting metabolic stability or helping someone remain eligible for treatment.
Even in these cases, clinics will usually monitor hydration, nutritional intake, and tolerance of stimulation medications closely. Appetite suppression, nausea, or gastrointestinal side effects can make stimulation more physically demanding, so decisions are often individualised rather than routine. The aim is to support the body through stimulation without adding unnecessary strain.
Once embryo transfer enters the picture, clinic guidance becomes far more consistent. Nearly all fertility clinics require GLP-1 medications to be stopped before transfer, whether the transfer is fresh or frozen. This is because embryo transfer marks the point at which pregnancy becomes possible, and these medications are not approved for use in pregnancy. At that stage, the priority shifts away from metabolic support and firmly toward minimising any potential exposure during early implantation and development.
Use of GLP-1 medications during pregnancy is therefore not recommended, and clinics build stopping timelines around this principle rather than around proven harm. This approach reflects how risk is managed in fertility care more broadly. When evidence is still emerging, clinics tend to act cautiously, particularly during stages that directly affect pregnancy outcomes. The result is a set of practices that may feel strict but are designed to protect early pregnancy conditions while still allowing flexibility earlier in the IVF process where appropriate.
Planning your timeline: IVF with or after GLP-1s
Planning IVF alongside GLP-1 weight loss injections works best when you step back and look at the whole sequence, rather than treating weight loss, stopping medication, and IVF as separate decisions. Clinics are thinking in timelines, not moments, and having that same framework can reduce delays and last-minute stress.
Working backwards from embryo transfer
Embryo transfer is the anchor point in most IVF plans because it’s the moment pregnancy becomes possible. Clinics usually start here and work backwards when advising on GLP-1 use.
If you know whether you’re aiming for a fresh or frozen transfer, your team can map out when GLP-1 medication needs to stop, allowing time for drug clearance and physiological settling. Frozen transfer cycles often offer more flexibility, as stimulation, retrieval, and transfer are separated. Fresh transfers compress the timeline and usually require earlier discontinuation.
Thinking in reverse like this helps avoid situations where everything is ready to go, but transfer is delayed because stopping guidance wasn’t built in early enough.
Building in a weight stabilisation phase
Weight loss itself is rarely the end goal before IVF. Clinics are usually looking for stability, not continued rapid loss.
A stabilisation phase allows appetite cues to normalise after stopping medication, energy intake to become consistent, weight to plateau rather than fluctuate, and your body to shift from a weight-loss state into a maintenance state
This matters because early pregnancy and implantation are metabolically demanding. A body that is still actively losing weight is in a very different physiological state to one that has settled, even if the number on the scale is the same.
Supporting nutritional rebuild and adequacy
GLP-1 medications can make it harder to meet nutritional needs, especially protein, iron, B vitamins, and overall calorie intake, due to the appetite suppression. During IVF preparation, clinics are paying attention to whether the body is resourced enough to respond to stimulation and recover well from egg collection.
A planning window after stopping medication allows time to re-establish regular meals, increase protein intake comfortably, address any deficiencies identified in blood work, and improve hydration tolerance. It’s about ensuring the body has what it needs at a point where demand increases.
Allowing hormonal and cycle signals to settle
Stopping GLP-1s can temporarily affect hunger hormones, insulin signalling, and cycle patterns. For people tracking ovulation or preparing for hormone-timed transfer cycles, this adjustment period can make a real difference.
Giving your body time to settle can improve clarity around cycle length and ovulation, reduce confusion in hormone monitoring, and help make protocol timing more predictable
This is particularly relevant for people with PCOS or irregular cycles, where stability often matters more than speed.
Planning for the emotional adjustment after stopping
This part is often underestimated. Coming off appetite-suppressing medication can bring a return of hunger, food noise, or anxiety around weight regain, especially in the middle of an already emotional fertility path.
Planning ahead allows space to set realistic expectations about appetite changes, put support in place if food feels emotionally loaded, separate weight maintenance from self-worth, and reduce the pressure to “hold everything together” perfectly.
Clinics don’t always name this explicitly, but it’s a real part of the transition, and acknowledging it early can make IVF feel more manageable.
Coordinating care between providers
Many delays happen not because of medical issues, but because care isn’t joined up. Weight loss injections are often prescribed outside fertility clinics, so planning works best when timelines are shared.
This might include aligning stopping guidance between prescriber and clinic, making sure both teams understand your IVF protocol, and clarifying who to contact if cycles shift or plans change.
Coordination reduces mixed messages and puts you back in control of the process.
NHS IVF Eligibility Calculator
Trying to find out if you qualify for NHS-funded IVF or IUI treatment? Between postcode rules and unclear criteria, it can be hard to know where you stand.
Questions to ask your fertility clinic (and prescribing doctor)
These conversations matter. Clear, early discussions can prevent delays, mixed messages, and last-minute changes at points where you’re already carrying enough emotional weight.
Consider asking:
- What is your policy on GLP-1 medications during stimulation? Clinics vary in how they approach GLP-1 use during ovarian stimulation. Understanding whether your clinic allows continued use up to egg retrieval, or prefers stopping earlier, helps you plan realistically and avoid having to pause treatment unexpectedly.
- When do you require stopping before embryo transfer? This is one of the most important questions to ask early. Clarifying how far in advance your clinic requires GLP-1 medications to be stopped, and whether this differs for fresh versus frozen transfers, gives you a clear timeline to work towards rather than relying on assumptions.
- Do you consider medical weight loss support in BMI-related decisions? If BMI thresholds apply to your care, it’s worth asking how your clinic views medically supported weight loss. Some clinics take a more flexible, individualised approach when weight loss is supervised and stable, while others apply strict cut-offs regardless of context.
- How do you support appetite rebound and nutrition after stopping medication? Stopping GLP-1s can bring changes in appetite and eating patterns. Asking what nutritional guidance, referrals, or monitoring your clinic offers can help you feel supported rather than left to manage this transition alone.
- How do you coordinate care with prescribing clinicians? IVF care and weight loss prescribing often sit in different systems. Clarifying how information is shared, who leads on stopping guidance, and who to contact if plans shift can prevent confusion and ensure your care feels joined up.
Clear answers build trust and reduce last-minute surprises. They also give you a stronger sense of partnership with your care team, which matters just as much as protocols when you’re navigating complex decisions around IVF and weight loss support.
IVF, weight loss injections, and informed choice
There’s no single right answer when it comes to IVF and weight loss injections, because fertility care is never one-size-fits-all. Decisions around GLP-1 medications depend on your health history, access to treatment, emotional readiness, and timing, and those factors look different for everyone.
What consistently matters most is not weight alone, but safety and timing. Clinics are weighing pregnancy exposure, nutritional adequacy, and physiological stability, while patients are balancing metabolic health, eligibility criteria, and the reality of limited time. It’s reasonable to care deeply about both. Wanting to optimise your health and move forward with family building are not competing priorities.
The aim is not to get everything “perfect” before IVF. The aim is to make informed choices, based on evidence and personal context, rather than pressure or assumptions. With clear information and open conversations, it becomes easier to plan next steps that protect your health, respect your fertility timeline, and leave you feeling supported rather than rushed.
Weight loss injections and IVF: FAQs
Does Mounjaro affect IVF success?
There’s no evidence that Mounjaro directly improves IVF success rates. Its role is supportive rather than enhancing, often helping people meet treatment criteria or manage metabolic conditions that can complicate fertility care. What matters most for IVF outcomes is how and when the medication is used, particularly around embryo transfer. Clinics focus far more on timing and safety than on the medication itself.
Is it safer to delay IVF until after weight loss?
For some people, delaying IVF to focus on weight loss can reduce treatment risks and improve access, particularly where BMI thresholds apply. For others, age, ovarian reserve, or previous delays make waiting feel less straightforward. Safety is part of the decision, but so is timing, and these factors need to be weighed together rather than in isolation. This is why personalised guidance from your fertility team matters more than general rules.
Will clinics refuse IVF if I’m on GLP-1s?
Most clinics don’t refuse IVF simply because someone is using a GLP-1 medication. Instead, they usually focus on when the medication is stopped in relation to stimulation and embryo transfer. Clear communication and planning are often enough to align treatment timelines with clinic policies. Problems tend to arise when medication use isn’t discussed early rather than because of the medication itself.
Do I need to tell my clinic or doctor that I’m on weight loss medication?
Yes, it’s important to tell both your fertility clinic and your prescribing doctor if you’re using weight loss medication. This helps ensure treatment plans, stopping timelines, and monitoring are aligned across your care team. Sharing this information early also reduces the risk of delays or conflicting advice later on. Open communication allows decisions to be made collaboratively, with your safety and fertility goals at the centre.
Sources
- NHS England. Medicines for obesity.
- Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/.
- World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. 1 December 2025.
- NHS England. Weight management injections.
- Hoteit BH, Kotaich J, Ftouni H, Hazime F, Safawi A, Masri R, Marwani M. The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials. Ther Adv Endocrinol Metab. 2025 Oct 7;16:20420188251383064. doi: 10.1177/20420188251383064. PMID: 41069706; PMCID: PMC12504844.
- EMC. Mounjaro KwikPen 10mg solution for injection in pre-filled pen. Medicine information. 17 Nov 2025.
- EMC. Ozempic 0.5 mg solution for injection in pre-filled pen. Medicine information. 1 Dec 2025.
- EMC. Wegovy 0.5 mg, FlexTouch solution for injection in pre-filled pen. Medicine information. 1 May 2025.
- EMA Europa. Ozempic, semaglutide information leaflet.
- EMC. Saxenda 6 mg/mL solution for injection in pre-filled pen. Medicine information. 27 Nov 2025.
- EMA Europa. Saxenda, liratide information leaflet.
- National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity. Technology appraisal guidance. Reference number: TA1026. Published: 23 December 2024. Last updated: 1 September 2025.
- NHS Barnsley Hospital, NHS Foundation Trust. GLP-1 agonists: Liraglutide (Victoza®) Lixisenatide (Lyxumia®) Dulaglutide (Trulicity®) Semaglutide (Ozempic®▼ injection and Rybelsus® ▼oral tablets) Amber G guideline. Date Approved: 11/10/2023.
- UK Teratology Information Service. USE OF ORLISTAT IN PREGNANCY. Date of issue: July 2022, Version: 4.
- EMA Europa. Mysimba information leaflet.
- Tommy’s. Tips for a healthy pre-pregnancy diet. Reviewed: 29 August 2023.
- NHS. IVF. Page last reviewed: 15 April 2025.
- Farzam K, Patel P. Tirzepatide. [Updated 2024 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585056/.
- Drugs.com. Mounjaro side effects to be aware of. Medically reviewed by Melisa Puckey, BPharm. Last updated on Sep 10, 2025.
- National Institute for Health and Care Excellence. Semaglutide.
- National Institute for Health and Care Excellence. Liraglutide.
- National Institute for Health and Care Excellence. Tirzepatide.
- NHS Worcestershire Acute Hospitals; NHS Trust. Lifestyle Advice for Fertility Patients.
- Fraser D, Lam B, Kristan MM. MON-150 Restoration of Fertility in Polycystic Ovarian Syndrome with Glucagon-Like Peptide-1 Therapy. J Endocr Soc. 2025 Oct 22;9(Suppl 1):bvaf149.1887. doi: 10.1210/jendso/bvaf149.1887. PMCID: PMC12546052.
- Jeong HG, Cho S, Ryu KJ, Kim T, Park H. Effect of weight loss before in vitro fertilization in women with obesity or overweight and infertility: a systematic review and meta-analysis. Sci Rep. 2024 Mar 14;14(1):6153. doi: 10.1038/s41598-024-56818-4. PMID: 38486057; PMCID: PMC10940611.
- Jacobsen DP, Røysland R, Strand H, Moe K, Sugulle M, Omland T, Staff AC. Cardiovascular biomarkers in pregnancy with diabetes and associations to glucose control. Acta Diabetol. 2022 Sep;59(9):1229-1236. doi: 10.1007/s00592-022-01916-w. Epub 2022 Jul 7. PMID: 35796791; PMCID: PMC9329411.